Genital herpes, caused by herpes simplex virus type-2 (HSV-2) or type-1 (HSV-1), affects over 45 million people in the United States [1, 2] . Both viruses are members of Herpesviridae and belong to the subfamily of Alphaherpesvirinae [3] . Most people contract HSV-2 or HSV-1 infection from another person through asymptomatic viral shedding. Alphaherpesviruses typically become latent in the sensory or dorsal root ganglia following a primary infection. The latent infection can be reactivated when the host is stressed or immunosuppressed, leading to the production of infectious virus at peripheral sites, such as the genital tract [3] . Genital HSV-2 reactivates 6× more frequently than HSV-1 [4] [5] [6] . There is no treatment that can prevent virus reactivation from latency; therefore, the development of a novel topical anti-HSV microbicide that is effective at blocking transmission or initial infection would be clinically useful.
In this study, we describe the evaluation of the antiviral activity of antisense peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) against HSV-2 in cell cultures and in two animal models. Phosphorodiamidate morpholino oligomers (PMOs) are single-stranded nucleic acid analogues with a modified backbone composed of nitrogen-containing morpholine rings with phosphorodiamidate intersubunit linkages [7] . PMOs are water-soluble, resistant to cellular
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Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers Introduction nucleases and are typically synthesized to a length of 20-25 bases [7] . PMOs can hybridize to complementary messenger RNA (mRNA) sequences and inhibit translation through steric blocking [8] . A PPMO is created by conjugating an arginine-rich, cell-penetrating peptide to the 5′-end of a PMO. This has been shown to greatly enhance cellular uptake [9, 10] . PPMOs have been shown to inhibit infections of a number of RNA viruses in a sequence-specific and dose-dependent manner in both cell cultures and mouse models [11] . PPMOs have also been shown to be capable of specifically reducing gene expression of Kaposi's sarcoma-associated herpesvirus [12, 13] . We previously showed that PPMOs targeting the immediate early protein (ICP)0 and ICP27 mRNA of HSV-1 were highly effective at blocking HSV-1 replication in cell cultures and at reducing HSV-1 ocular disease in mice [14] . In this study, we investigated the antiviral activities of four PPMOs targeted against two HSV-2 immediate early genes, ICP0 and ICP27, and two early genes, unique long gene (UL)30 and UL39.
Methods

Cells and viruses
Vero cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), penicillin (100 U/ml) and streptomycin (100 µg/ml; Sigma-Aldrich, Inc., St Louis, MO, USA). HSV-2 strain G (G) was obtained from American Type Culture Collection (catalogue number VR-734; Manassas, VA, USA). HSV-2 (H4805) is an acyclovir (ACV)-resistant clinical isolate [15] .
PPMO synthesis
All PPMOs were synthesized at AVI BioPharma, Inc. (Corvallis, OR, USA), as previously described [7, 16] . PPMO sequences and their target locations are described in Figure 1 . A PPMO of random sequence (named as 'SCR') containing 50% G/C content was synthesized in the same manner and used as a negative control throughout this study.
In vitro cytotoxicity assays
As previously described [14] , 96-well plates were seeded with approximately 1×10 4 Vero cells and grown overnight at 37°C and 5% CO 2 . The cells were washed once with 1× phosphate-buffered saline (PBS) without Ca 2+ and Mg 2+ (Invitrogen) and treated with the indicated concentrations of PPMOs diluted in 100 µl PBS. Cell viability assays were carried out with CellTiter-Blue reagent (Promega, Madison, WI, USA) as previously described [14] .
Effect of PPMO treatment against HSV-2 replication in vitro
Twelve-well plates were prepared the day before infection by seeding each well with approximately 2.5×10 5 Vero cells. The cells were washed once with PBS and treated with 0.2 ml of 20 µM PPMO in PBS. Following a 2 h treatment, the cells were washed twice with PBS and infected with HSV-2 (G) at a target input of 1,000 plaque-forming units (PFU)/well. Following 1 h absorption, the cells were washed once with PBS and maintained in the culture medium. At 24, 48 and 72 h post-infection (hpi), the total amount of infectious virus was determined by standard plaque assay on Vero cells as previously described [14] .
Plaque reduction assay with PPMO treatment before infection
Vero cells were seeded in six-well tissue culture plates at approximately 1×10 6 cells/well on the day before drug treatment. Three wells were treated with 0.5 ml of an indicated PPMO at each selected concentration and incubated for 2 h. After a 2 h exposure, the cells were washed twice with PBS and then infected with HSV-2 (G) or HSV-2 (H4805) at 200-300 PFU/well. Following a 1 h viral absorption, 3 ml of methylcellulose overlay media [14] was added to each well. Plates were incubated at 37°C with 5% CO 2 in a humidified incubator. Plaques were visualized at 3-4 days post-infection (dpi) by staining with 1% crystal violet in 20% methanol.
Plaque reduction assay with PPMO treatment after infection
Twelve-well plates of Vero cells were prepared as described earlier, then infected with HSV-2 (G) at 200-300 PFU/well as described previously [14] . At 6 or 12 hpi, the cells were treated with 0.2 ml PPMO at the indicated concentrations. Plaque assays were carried out as described earlier.
Determination of a tolerable dose of PPMO in uninfected animals
Six-week-old inbred female Sigmodon hispidus cotton rats (weighing approximately 80 g each) were obtained from Virion Systems, Inc. (Rockville, MD, USA). Eight-week-old inbred female BALB/c mice (weighing approximately 20 g each) were obtained from Harlan Laboratories, Inc. (Indianapolis, IN, USA). To maintain dosing similar to that used in the cell culture experiments, we increased the PPMO concentrations 10-fold and reduced the application volume 10-fold [14] . To investigate dose tolerance, three groups of three rats or mice were exposed to 20 µl (BALB/c mice) or 100 µl (cotton rats) of 100 µM, 200 µM or 1 mM ICP0 PPMO (BALB/c mice), or ICP27 PPMO (cotton rats) diluted in PBS, or PBS alone, by direct administration to the vaginal vault via a pipette. Prior to administration of PPMO, the vaginal vault of each animal was gently cleaned with a PBS-wetted Dacron ® Fiber (Dacron, Guilford, MA, USA) tipped swab followed by a dry Dacron ® Fiber (Dacron) tipped swab.
Each group of rats or mice received the same dose of PPMO daily for 7 days. The overall appearance and behaviour of the animals were observed daily. On day 7 post-treatment, the rats and mice were euthanized, and vaginal tissue was examined microscopically following fixation in 10% neutral buffered formalin, routine processing into paraffin blocks and staining of cut sections with haematoxylin and eosin.
Evaluation of PPMO treatment against HSV-2 infection in cotton rats
All rats were injected subcutaneously with 2 mg medroxyprogesterone acetate (Sicor, Irvine, CA, USA) to prevent ovulation and were infected vaginally with HSV-2 (G) 1 week later [17, 18] . The vaginal vault of each animal was cleaned as described previously and inoculated with 100 µl of HSV-2 (G; 2×10 5 PFU) per animal using a pipette. At 24 hpi, each group was treated with 100 µl of PBS, PBS containing 100 µM ICP27 or SCR PPMO, respectively, by direct administration to the vaginal vault via pipette. Similarly, at 24 h following a mock infection, separate groups were administered the same treatments, in the same manner as described earlier. All treatments were given daily for 5 days. Viral shedding was determined by swabbing the vaginal cavity on 1, 3, 5, 7 and 14 dpi. Gross lesions were graded according to a 4-point scale: 1= slight genital oedema, 2= moderate genital inflammation, 3= purulent genital lesion and 4= death.
Evaluation of PPMO treatment against HSV-2 infection in mice
Female 8-week-old BALB/c mice were subcutaneously injected with 2 mg medroxyprogesterone acetate (Sicor). Mice were infected vaginally 1 week later with HSV-2 (H4805) and treated with PPMOs. A total of five groups (eight mice per group) were treated with 20 µl of PBS, PBS containing 100 µM of ICP27, ICP27/0 (an equal combination of ICP27 and ICP0), SCR PPMO or ACV for 2 h before intravaginal infection with 2×10 4 PFU of HSV-2 (H4805; 20 µl of 2×10 3 PFU/µl). Another five groups (five mice per group) received the same treatments, but at 24 hpi. Each mouse received one treatment. To monitor virus replication, genital swabs were taken at 1, 3, 5, 7, 10 and 14 dpi. The overall appearance and behaviour of the mice was observed daily. On day 7 post-treatment, two mice from each treatment group were euthanized, and vaginal tissues were collected and examined microscopically as described previously.
Statistical analyses
All statistical analyses were performed using GraphPad Prism version 4 for Windows (GraphPad Software, San Diego, CA, USA). Plaque reduction results were analysed by two-way ANOVA with Bonferroni post hoc tests.
Results
PPMO design
Previous studies have shown that the region immediately 5′ of and spanning the translation start site of viral mRNA frequently constitutes an effective targetregion for PMO technology [11] . ICP27, ICP0, UL30 and UL39 are considered to be essential genes in the HSV-2 replication life cycle and are highly conserved, containing little sequence variation between HSV-2 isolates [3, [19] [20] [21] [22] . We therefore designed the four anti-HSV-2 PPMOs to be complementary in sequence to the AUG region for the mRNA of each gene ( Figure 1 ). All PPMO sequences were screened with BLAST against mouse, rat and human mRNA sequences, and the negative control PPMO, SCR, was also screened against all HSV-1 and HSV-2 sequences to preclude unintentional hybridization events.
Cytotoxicity assay of PPMO in vitro
To investigate PPMO-associated cytotoxicity, uninfected Vero cells were treated with the PPMOs used in this study and then subjected to a cell-viability assay. Figure 2 shows viability results from Vero cells treated with ICP27, ICP0, UL30 and UL39 over a concentration range of 5-40 µM. No significant difference in viability was apparent between mock-treated cells and those treated with up to 40 µM of SCR, ICP27, ICP0 or UL30. The UL39 PPMO produced slight toxicity at 20 µM. All PPMOs in this study were used at ≤20 µM for the remainder of the cell culture experiments.
Effect of PPMO treatment against HSV-2 replication in vitro
Our previous study found that PPMOs applied before infection had potent activity against HSV-1 replication [14] . To evaluate the effect of individual PPMOs applied before infection, Vero cells in 12-well plates were treated with each PPMO for 2 h before infection with HSV-2 (G) at 1×10 3 PFU/well. Viral replication was measured at 24, 48 and 72 hpi as described previously. As shown in Figure 3A , ICP27 and ICP0 PPMOs each reduced the number of PFU/ml by 2 log 10 or more at 24 hpi. The difference between ICP27 or ICP0 PPMO and controls (SCR-or mock-treated) showed statistical significance (P<0.001). At 48 and 72 hpi, ICP27 reduced virus replication by 2-3 log 10 PFU/ml, whereas ICP0 caused approximately a 2 log 10 PFU/ml reduction, which was also statistically significant when compared with the SCR-or mock-treated controls (P<0.001). No significant reduction was seen in cells treated with SCR and UL30 or UL39 PPMOs (LJ, data not shown). These data indicated that the PPMOs targeting ICP27 and ICP0 were capable of significantly and specifically reducing the replication of HSV-2 (G); therefore, these two PPMOs were chosen for further study.
PPMO dose effect against HSV-2 replication
PPMO dose effect before infection was evaluated by standard plaque reduction assays. As shown in Figure 3B , the ICP27 PPMO was the most effective PPMO against HSV-2 replication, reducing plaque formation by 28% at 5 µM, 66% at 10 µM and 88% at 20 µM, compared with mock treatment. The ICP0 PPMO reduced plaque formation by 47% at 5 µM, 55% at 10 µM and 73% at 20 µM. The SCR PPMO had no inhibition effect and produced nearly identical results to the mock treatment when cells were infected with either of the two strains of HSV-2 ( Figure 3B ). These results demonstrate that ICP27 PPMO strongly, and ICP0 PPMO moderately, reduced virus replication when applied before HSV-2 infection.
Effect of post-infection PPMO treatment on HSV-2 replication
To determine the efficacy of PPMO treatment that commenced after HSV-2 (G) infection, Vero cells were treated with PPMO for 2 h starting at 6 or 12 hpi. As shown in Figure 3C , when treatment began at 6 hpi, 20 µM ICP27 and ICP0 PPMOs reduced plaque formation by 92% and 54%, respectively, when compared with the mock treatment. At a similar concentration, ACV reduced plaque formation by 85%. The difference in plaque reduction between the 20 µM ICP27 and SCR PPMO treatment was statistically significant when the treatment began at 6 hpi (P<0.001). As evaluated by our statistical analysis, all PPMOs at a dose of 20 µM were ineffective when applied at 12 hpi; however, although there was no statistically significant reduction between the 20 µM ICP27 PPMO and ACV with the SCR PPMO treatment, there was a 35% and 40% reduction in plaque formation for ICP27 PPMO and ACV, respectively, at 12 hpi when compared with the mock treatment (P<0.001). These results indicate that the antiviral effect of PPMOs are similar or superior to ACV, but diminish with the period of time lapsed between infection and treatment application.
Effect of post-infection PPMO treatment on acyclovir-resistant HSV-2 replication
To determine the efficacy of PPMO treatment against ACV-resistant HSV-2 (H4805) replication, Vero cells were treated with PPMO for 2 h starting at 6 or 12 hpi. As shown in Figure 3D , when treatment began at 6 hpi, ICP27 and ICP0 PPMOs reduced plaque formation by 84% and 42%, respectively, when compared with the mock control. The difference in plaque reduction for 20 µM ICP27 or ICP0 PPMOs, compared with the SCR PPMO treatment applied at 6 hpi, was statistically significant (P<0.001 and P<0.05, respectively). Similar to the results previously, all PPMOs at a dose of 20 µM were ineffective when applied at 12 hpi. ACV and SCR had no inhibitory effects and produced nearly identical results to the mock-treated control. These results show that PPMOs were effective against both ACV-sensitive and ACV-resistant strains of HSV-2, but that they only were effective against ACV-resistant HSV-2 during the early phases of infection.
Determination of a tolerable dose of PPMO in uninfected animals
To establish a maximum tolerable dose, three groups of uninfected mice or cotton rats were topically administered with 20 µl of 100 µM, 200 µM or 1 mM ICP27 PPMO daily for 7 days. On day 7 post-treatment, no gross lesions were observed and microscopic examination revealed no histopathological changes in the genital tracts from all members of the three groups of mice. The histology of the genital tracts of mice treated with 100 µM ICP27 PPMO were similar in appearance to those of mock-treated mice (Additional file 1). The same pattern was observed in mice treated with 100 µM and 1 mM ICP27 PPMOs (LJ, data not shown). In addition, the PPMO treatment had no effect on body weight, temperature, appearance or overall behaviour of the mice over the 7-day observation period (LJ, data not shown). Similar results were observed in the uninfected cotton rats receiving the same treatments (Additional file 1).
The effect of PPMO against HSV-2 infection in cotton rats
PPMOs have been shown to produce dose-dependent toxicity in vivo in previous studies [11] . Because 100 µM PPMO was clearly well-tolerated by uninfected animals, as described above, and was an effective dose based on our in vitro studies, we decided to evaluate all PPMOs at this dose in vivo. To evaluate whether ICP27 PPMO could specifically reduce HSV-2 infection in the genital tract, three groups of cotton rats (eight per group) were inoculated with HSV-2 (G), then treated with PBS, ICP27 or SCR PPMO. Another three groups of cotton rats (five per group) were mock-infected with PBS and then treated in a similar manner to the infected cotton rats. No visible gross lesions were observed by 6 dpi in either treated or control groups. As summarized in Figure 4A , epithelial lesions developed at the vaginal opening beginning at 7 dpi and increased in size by 10 dpi in both mock-and SCR-treated groups. By 10 dpi, both mock-and SCR-treated groups developed inflammation, vesicles around the vaginal opening and severe pruritis leading to severe self-mutilation such as bleeding, tissue damage and loss of tails. All the animals in either the treated or control groups showed slight oedema in the genital opening, which probably resulted from the daily swabbing required in the treatment application. The ICP27 PPMO-treated group had significantly smaller gross lesions compared with the mock-and SCR-treated groups. Only one of eight ICP27 PPMO-treated animals, compared with four of eight mock-or SCR-treated animals, died by 14 dpi (Figure 4A and 4B) . Although statistically significant protection from ICP27 PPMO was not achieved in mortality, possibly because of relatively small group sizes, these results demonstrate that the ICP27 PPMO treatment can reduce genital lesions and lower mortality at 37.5% by 14 dpi in the cotton rat model. This suggests that reducing local infection can reduce host systemic response to HSV-2 infection. Although there was no statistically significant difference in virus replication between groups within the first 5 dpi, the ICP27 PPMO-treated groups had a 10-fold reduction in virus replication by 7 dpi, and there was no virus detectable by 10 dpi ( Figure 4C ).
The effect of PPMO against HSV-2 infection in mice
To determine the PPMO prophylactic efficacy against infection with ACV-resistant HSV-2, five groups of mice (eight per group) were treated with PPMO starting at 2 h before intravaginal infection with HSV-2 (H4805). To determine the PPMO therapeutic efficacy against H4805, another five groups (five mice per group) received the same PPMO treatments at 24 hpi. As shown in Figure 5A , when the PPMO was administered at 2 h before infection, the ICP27, ICP27/0 and ACV treatment groups all showed significant reduction of HSV-2 (H4805) replication at 3 dpi, when compared with the mock-treated group (P<0.001; Figure 5A ). The SCR-treated animals showed no significant reduction when compared with the mock-treated group. When treatments were applied at 24 hpi, ICP27/0 PPMOs reduced virus replication by approximately 10-to 25-fold at both 3 and 5 dpi when compared with the SCR-or mock-treated controls, whereas ICP27 PPMO produced an approximate 5-to 10-fold reduction at 5 dpi ( Figure 5B ). The ICP27/0 treatment groups had a statistically significant reduction of HSV-2 (H4805) replication at 3 dpi when compared with the SCR-treated control ( Figure 5B; P<0.05) . These results indicate that, in vivo, ICP27 and ICP0 PPMOs can reduce HSV-2 replication when applied either 2 h before infection or 24 hpi. It appears that ACV still has an antiviral effect on 3 dpi (Figure 5A and 5B). It is possible that ACV, at a high dose, was still effective against this strain during early infection, but was ineffective during later infection (after day 5), because this strain had only point mutations in its thymidine kinase gene [15] . In this study, no deaths occurred in any of the groups by 14 dpi, nor were any gross lesions observed in the genital tract openings of any mice. We observed slight oedema and redness in individuals from all treatment groups, which probably resulted from the daily swabbing required to monitor virus replication. All mice recovered by 20 dpi and no microscopic histological damage was observed in any of the animals from the various groups checked at 20 dpi (LJ, data not shown). These results suggest that PPMO can be effective in a prophylactic or therapeutic treatment against HSV-2 (H4805) infection.
Discussion
In this study, PPMOs targeting the AUG start site regions of HSV-2 mRNAs for immediate early genes, ICP0 and ICP27, were found to be highly effective in cell cultures against two strains of HSV-2, with one of the strains being ACV-resistant (H4805; Figure 3) . The results here are consistent with our previous study, which showed that PPMOs inhibiting HSV-1 ICP0 and ICP27 mRNA translation were effective at reducing viral replication and ocular disease in mice [14] . Antisense oligonucleotides targeted against HSV-1 UL39 DNA have previously been reported to produce inhibition against HSV-1 infection (United States patent 5248670); however, the PPMOs targeted against HSV-2 UL30 and UL39 mRNA did not produce significant reduction of viral replication or spread. The early genes, UL30 and UL39, encoding the viral DNA polymerase and large subunit of the ribonucleotide reductase, respectively, are required for HSV-2 DNA replication. It is unclear if the PPMOs targeting UL30
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Number of rats and UL39 were ineffective because they did not inhibit mRNA translation effectively or because a reduction in the protein product of these genes did not affect viral replication to a significant level in our cell culture system. Unfortunately, no commercial antibodies were available to us to examine the levels of these viral proteins. Because the PPMOs were designed to interfere with translation, it is not expected that mRNA levels would be affected. As anticipated, our results show that PPMO treatment applied before infection in cell cultures is more effective than post-infection treatment; however, PPMO treatment of cell cultures starting at 6 hpi did produce considerable antiviral efficacy.
Cotton rats are susceptible to HSV-2 infection and produce disease symptoms similar to those found in humans [18] . Because the ICP27 and ICP0 PPMOs were effective against HSV-2 in vitro, we went on to evaluate their efficacy in vivo in cotton rats. We found that cotton rats inoculated intravaginally with 1×10 4 PFU/rat did not display severe illness nor was virus replication detectable by vaginal swabbing (LJ, data not shown); however, inoculation with 2×10 5 PFU/ rat did cause epithelial lesions at the vaginal opening and death in 50% of the animals. Although the ICP27 PPMO did not completely block HSV-2 replication, it did reduce HSV-2 replication by 7 and 10 dpi and lowered the death rate ( Figure 4B ). Animals that died from HSV-2 infection had spleen necrosis and a urinary tract infection, indicating systemic infections with secondary bacterial infections from traumatized genital lesions (LJ, data not shown). The reduction of HSV-2 replication might have allowed a more effective host immune response to occur and consequently lower mortality associated with HSV-2 systemic infection. The finding that HSV-2 infection can cause death in the cotton rat has not been previously reported.
HSV-2 infection can cause high mortality in mice [23, 24] . To test whether PPMOs can protect against ACV-resistant HSV-2 infection, we infected mice with HSV-2 (H4805), an ACV-resistant clinical isolate [15] . An inoculation of 2×10 4 PFU [17] did not produce any mortality in our study, which is in agreement with ACV-resistant strains reportedly being less virulent [25] ; however, the virus did replicate in the genital tract to a level that was sufficient for us to evaluate the potential antiviral effect of drug applications (Figure 5) . The dose of ACV we used showed anti-HSV-2 efficacy at early infection but this disappeared at 5 dpi. The ICP27 PPMO given alone or in combination with ICP0 was able to reduce viral replication when administered prophylactically and a combination of the ICP27 and ICP0 PPMOs was also effective when administered at 24 hpi.
Our in vitro study suggested that PPMOs are considerably more effective if applied before infection (Figure 3) ; however, our in vivo study demonstrated that PPMOs can significantly suppress HSV-2 infection even when first administered at 24 hpi (Figures 4 and 5) . The difference between our in vivo and in vitro studies might reflect an innate immune response against HSV-2 infection. It normally takes 24 h before any virus replication is detectable in vivo; therefore, initial PPMO treatment at 24 hpi might be early enough in the infectious cycle to prevent virus replication at the vaginal mucus surface. In conclusion, our studies demonstrated that ICP0 and ICP27 PPMOs are effective antivirals against HSV-2 infection in vitro and in vivo. Our results suggest that PPMOs have potential to serve as prophylactic or therapeutic treatments against HSV-2 infection, including ACV-resistant strains. The ICP27 and ICP0 PPMO compounds warrant consideration for further drug development evaluations.
